How people respond to therapy for rectal cancer
Rectal cancer is a common form of colorectal cancer. Although everyone with rectal cancer receives chemoradiotherapy, up to 40% of people will not respond to treatment. This leaves them undergoing aggressive treatment for no benefit.
April 2018 - March 2021
Charity information: Bowel & Cancer Research
Rectal cancer occurs in the lower bowel, just above the anus, the rectum. It is one of the most common forms of bowel cancer.
Currently patients diangosed with rectal cancer will undergo chemo-radiotherapy before surgery with the aim of reducing the size of the tumour in order to make the surgery more effective.
Responses to this vary widely, with up to 40% of people gaining no benefit at all from this therapy.
The team have identifed a specific gene which they think is prevents cancer cells dieing. Their aim is to understand the mechanism by which the cells are protected from cell death.
They will use 2D and 3D cell culture models, clinical samples and population based studies to see whether the interactions of related genes could explain why current treatments fails some individuals.
To understand why some people fail to respond to chemo-radiotherapy when treated for rectal cancer.
Activities» We will undertake medical research to find the answer.
What success will look like
At the end of the project the researcher will have identified whether the protein they are looking at does play a role in response to treatment.
Ultimately we wish to identify a
The risk, as always with medical research, is that the original hypothesis - that our protein of interest is a marker of response - does not do so. Over the course of 3 years the research team will respond to findings as they arise which may mean that new avenues come to light as a result of this work.
We report to donors each year as the research team reports to us.
Budget - Project Cost: £6,735Loading graph....
Amount Heading Description £6,735 consumables tissue culture and plastic ware
The project will take place at the School of Cellular and Molecular Medicine at the University of Bristol.
Individuals diagnosed with rectal cancer.
We fund the best science across the UK into bowel cancer and other bowel diseases and run a specialised PhD studentship programme which this project will be part of.
Read more about the Charity running this project.
Professor Ann Williams
She is Professor of Experimental Oncology and will supervise the PhD student.